WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Blue Matter
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
PHARMA TECH
Novartis | January 19, 2021
Novartis plunked down up to $2.2 billion for BeiGene's China-approved PD-1 drug tislelizumab to complement its own checkpoint inhibitor. Hear what BeiGene CEO John Oyler has to say about tislelizumab's position in and outside China. Sinovac's COVID-19 vaccine reported confusing data from Brazil, raising doubt about its true efficacy. Celltron's anti-SARS-CoV-2 antibody improved patients' outcomes in a phase 2/3 trial. And more. Novartis paid $650 million upfron...
BUSINESS INSIGHTS
Dicerna Pharmaceuticals, Inc. | December 27, 2021
Dicerna Pharmaceuticals, Inc. announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021. As previously announced on November 18, 2021, Novo Nordisk commenced a cash tender offer to purchase all outstanding shares of Dicerna common stock for $38.25 per share in cash, without interest and subject to any wit...
PharmaTimes | January 30, 2020
The company has initiated efforts to broadly collaborate with others in order to screen a library of antiviral therapies, hoping to identify compounds with antiviral activity against the virus – which is also known as 2019-nCoV or Wuhan coronavirus. Using its AdVac and PER.C6 technologies - the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine - J&J has revealed plans to try and rapidly upscale production of the optimal...
Biohaven Pharmaceutical Holding Company Ltd. | October 14, 2020
Biohaven Pharmaceutical Holding Company Ltd. today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) goal date for completion of the FDA review of the preventive sNDA is set for 2Q2021. Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "Patients with mi...
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE